adalimumab - adalimumab - adaz injection, solution
(Adalimumab-Adaz)Sandoz Inc
Antibodies, Monoclonal [CS] class drugs
31 results
adalimumab - bwwd - adalimumab - bwwd solution
(Adalimumab-Bwwd)Organon Llcadalimumab-bwwd
(Adalimumab-Bwwd)Cordavis Limitedamjevita - adalimumab - atto injection
(Adalimumab-Atto)Nuvaila Limitedamjevita - adalimumab - atto injection
(Adalimumab-Atto)Amgen Usa Inc.amjevita - adalimumab - atto injection
(Adalimumab-Atto)Amgen, IncUsage: TNF blocker for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and eligible pediatric patients.bavencio - avelumab injection, solution, concentrate
(Avelumab)Emd Serono, Inc.Usage: Bavencio (avelumab) is a PD-L1 blocking antibody indicated for metastatic Merkel cell carcinoma (adults and patients 12+), locally advanced or metastatic urothelial carcinoma (maintenance after platinum chemotherapy or following progression on platinum chemotherapy), and advanced renal cell carcinoma (first-line, with axitinib).darzalex - daratumumab injection, solution, concentrate
(Daratumumab)Janssen Biotech, Inc.Usage: DARZALEX treats multiple myeloma in adults — used in newly diagnosed patients ineligible or eligible for stem cell transplant, and in relapsed/refractory cases after one or more prior therapies, as part of various combination regimens or as monotherapy.darzalex faspro - daratumumab and hyaluronidase - fihj
(Daratumumab And Hyaluronidase-Fihj (Human Recombinant))Janssen Biotech, Inc.Usage: DARZALEX FASPRO treats adult patients with multiple myeloma (newly diagnosed or relapsed/refractory, across various combination regimens), high-risk smoldering multiple myeloma, and newly diagnosed light chain (AL) amyloidosis. Not recommended for AL amyloidosis with NYHA Class IIIB/IV cardiac disease outside clinical trials.dupixent - dupilumab injection, solution
(Dupilumab)Sanofi-Aventis U.S. LlcUsage: DUPIXENT treats moderate-to-severe atopic dermatitis (6 months+), asthma (6 years+), chronic rhinosinusitis with nasal polyps (12 years+), eosinophilic esophagitis (1 year+), prurigo nodularis, COPD, chronic spontaneous urticaria (12 years+), bullous pemphigoid, and allergic fungal rhinosinusitis in eligible adult and pediatric patients.